TMThermo Fisher Scientific company profile
$700.22+0.11%Close 13 Nov 2026
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. provides products and services for science, healthcare and industry through five reporting segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. Its offerings include reagents, instruments and consumables for biological research and bioproduction, analytical instruments such as chromatography, mass spectrometry and electron microscopy, diagnostic test kits and culture media, laboratory consumables and chemicals, and outsourced pharma development, manufacturing and clinical research services. Customers include pharmaceutical and biotechnology companies, hospitals and clinical laboratories, universities, research institutions and government agencies. The company sells through a direct sales force, electronic commerce and third-party distributors and operates globally, with colleagues in the Americas, Asia-Pacific, and Europe, the Middle East and Africa.
A summary of the business section of the company's latest annual report, filed 26 Feb 2026.
Company facts
| Ticker | TMO · NYSE |
|---|
| Sector | Instruments |
|---|
| Industry | Life Sciences Tools & Services |
|---|
| Index | S&P 500 |
|---|
| Fiscal year ends | 31 December |
|---|
| Reporting currency | USD |
|---|
| CIK | 97745 |
|---|
| Latest annual report | 10-K, filed 26 Feb 2026 |
|---|
Officers and directors
| Name | Role | Shares owned | Latest Form 4 |
|---|
| Marc N. Casper | Chairman & CEO · Director | 450K · < 1% | Shares withheld for tax, 28 Aug 2026 |
|---|
| Michel Lagarde | Executive Vice President | 170K · < 1% | Shares withheld for tax, 28 Feb 2026 |
|---|
| Stephen Williamson | Retiring Sr. VP and CFO | 145K · < 1% | Shares withheld for tax, 28 Feb 2026 |
|---|
| Frederick M. Lowery | Executive Vice President | 102K · < 1% | Shares withheld for tax, 28 Feb 2026 |
|---|
| Gianluca Pettiti | President & COO | 92.5K · < 1% | Sale under a 10b5-1 plan, 31 Aug 2026 |
|---|
| Scott M. Sperling | Director | 68.4K · < 1% | Gift, 28 Oct 2026 |
|---|
| Nelson J. Chai | Director | 14.3K · < 1% | Grant or award, 20 May 2026 |
|---|
| C. Martin Harris | Director | 8.5K · < 1% | Grant or award, 20 May 2026 |
|---|
| Tyler Jacks | Director | 8.4K · < 1% | Grant or award, 20 May 2026 |
|---|
| Dion J. Weisler | Director | 4.5K · < 1% | Shares withheld for tax, 20 May 2026 |
|---|
| James C. Mullen | Director | 2.8K · < 1% | Grant or award, 21 May 2025 |
|---|
| Ruby R. Chandy | Director | 2.4K · < 1% | Grant or award, 20 May 2026 |
|---|
| Debora L. Spar | Director | 1.5K · < 1% | Grant or award, 20 May 2026 |
|---|
| R. Alexandra Keith | Director | 1.5K · < 1% | Grant or award, 20 May 2026 |
|---|
| Jennifer M. Johnson | Director | 339 · < 1% | Grant or award, 20 May 2026 |
|---|
| Karen S. Lynch | Director | 171 · < 1% | Grant or award, 20 May 2026 |
|---|
| Britt Lisa P. | Sr. VP and Chief HR Officer | — | Open-market sale, 28 Oct 2026 |
|---|
| Meyer James | Sr. Vice President & CFO | — | Shares withheld for tax, 28 Aug 2026 |
|---|
| Shropshire Thomas B Jr. | SVP and General Counsel | — | Shares withheld for tax, 28 Aug 2026 |
|---|
| Shafer Michael D | Executive Vice President | — | Shares withheld for tax, 28 Aug 2026 |
|---|
Holdings as the latest proxy statement states them, all forms counted; the latest Form 4 line each filed. People appointed since the proxy are listed from their Form 4 filings.
TMO in the terminal
The business section of every annual report, officers' holdings and trades, and the company's filings as they arrive.